Julia Macente

Julia Macente

Auto-generated profile, based on publicly available information

Julia Macente

Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Nina NauwelaertsNina Nauwelaerts
Nina Nauwelaerts
JMJulia Macente
Julia Macente
NDNeel Deferm
Neel Deferm
Rodolfo Hernandes BonanRodolfo Hernandes Bonan
Rodolfo Hernandes Bonan
MHMiao-Chan Huang
Miao-Chan Huang
PAPieter Annaert
Pieter Annaert
Women commonly take medication during lactation. Currently, there is little information about the exposure-related safety of maternal medicines for breastfed infants. The aim was to explore the performance of a generic physiologically-based pharmacokinetic (PBPK) model to predict concentrations in human milk for ten physiochemically diverse medicines. First, PBPK models were developed for “non-lactating” adult individuals in PK-Sim/MoBi v9.1 (Open Systems Pharmacology). The PBPK models predicted the area-under-the-curve (AUC) and maximum concentrations (Cmax) in plasma within a two-fold error. Next, the PBPK models were extended to include lactation physiology. Plasma and human milk concentrations were simulated for a three-months postpartum population, and the corresponding AUC-based milk-to-plasma (M/P) ratios and relative infant doses were calculated. The lactation PBPK models resulted in reasonable predictions for eight medicines, while an overprediction of human milk concentrations and M/P ratios (>2-fold) was observed for two medicines. From a safety perspective, none of the models resulted in underpredictions of observed human milk concentrations. The present effort resulted in a generic workflow to predict medicine concentrations in human milk. This generic PBPK model represents an important step towards an evidence-based safety assessment of maternal medication during lactation, applicable in an early drug development stage.

12 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MNMartje Van Neste
Martje Van Neste
ABAnnick Bogaerts
Annick Bogaerts
Nina NauwelaertsNina Nauwelaerts
Nina Nauwelaerts
JMJulia Macente
Julia Macente
ASAnne Smits
Anne Smits
Karel AllegaertKarel Allegaert
Karel Allegaert
Physiologically based pharmacokinetic (PBPK) modelling is a bottom-up approach to predict pharmacokinetics in specific populations based on population-specific and medicine-specific data. Using an illustrative approach, this review aims to highlight the challenges of incorporating physiological data to develop postpartum, lactating women and breastfed infant PBPK models. For instance, most women retain pregnancy weight during the postpartum period, especially after excessive gestational weight gain, while breastfeeding might be associated with lower postpartum weight retention and long-term weight control. Based on a structured search, an equation for human milk intake reported the maximum intake of 153 mL/kg/day in exclusively breastfed infants at 20 days, which correlates with a high risk for medicine reactions at 2–4 weeks in breastfed infants. Furthermore, the changing composition of human milk and its enzymatic activities could affect pharmacokinetics in breastfed infants. Growth in breastfed infants is slower and gastric emptying faster than in formula-fed infants, while a slower maturation of specific metabolizing enzymes in breastfed infants has been described. The currently available PBPK models for these populations lack structured systematic acquisition of population-specific data. Future directions include systematic searches to fully identify physiological data. Following data integration as mathematical equations, this holds the promise to improve postpartum, lactation and infant PBPK models.

23 March 2023 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Closed access
ECEdilainy Rizzieri Caleffi‐Marchesini
Edilainy Rizzieri Caleffi‐Marchesini
FBFernanda Belincanta Borghi‐Pangoni
Fernanda Belincanta Borghi‐Pangoni
JMJulia Macente
Julia Macente
PCPriscila Chiamulera‐Mantovani
Priscila Chiamulera‐Mantovani
JMJosmar Mazucheli
Josmar Mazucheli
ADAndréa Diniz
Andréa Diniz

9 July 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
JMJulia Macente
Julia Macente
Nina NauwelaertsNina Nauwelaerts
Nina Nauwelaerts
JBJustine Marine Badée
Justine Marine Badée
Rodolfo Hernandes BonanRodolfo Hernandes Bonan
Rodolfo Hernandes Bonan
MHMiao‐Chan Huang
Miao‐Chan Huang
PAPieter Annaert
Pieter Annaert
Physiologically‐based pharmacokinetic (PBPK) modeling can support decision‐making on maternal medication use during breastfeeding. This study aimed to enhance lactation PBPK models in two ways. First, the utility of integrating permeability‐ versus perfusion‐limited distribution to human milk was explored using the Simcyp Simulator. Secondly, for permeability‐limited models, drug‐specific bidirectional intrinsic clearance across the blood‐milk barrier, predicted from drug physicochemical properties, was incorporated into lactation PBPK models. Initially, reference PBPK models were developed and verified against published clinical data. Geometric Mean Fold Error (GMFE; ~accuracy) and Average Fold Error (AFE; ~bias) for these models ranged from 1.13–1.51 and 0.68–1.42, respectively. These verified models were then extended to lactation PBPK models applying either permeability‐ or perfusion‐limited assumptions for drug distribution across the blood‐milk barrier. The lactation PBPK models were applied to predict drug concentrations in human milk and relative infant doses (RID) for 11 small molecule drugs with diverse physicochemical and disposition profiles. The models successfully predicted observed plasma PK, human milk concentration‐time profiles, and milk‐to‐plasma ratios. Nine drugs had RID values below the safety threshold of 25%, while levetiracetam and nevirapine showed relatively higher RIDs (up to 21%). Based on these findings, a decision tree is proposed to guide the selection between permeability‐ or perfusion‐limited distribution models in future lactation PBPK applications using Simcyp. This workflow can be extended beyond the 11 model drugs evaluated, supporting broader infant risk assessment for maternal medication during lactation.

18 September 2025 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
Karel AllegaertKarel Allegaert
Karel Allegaert
JMJulia Macente
Julia Macente
DMDjalila Mekahli
Djalila Mekahli
Johannes Van den AnkerJohannes Van den Anker
Johannes Van den Anker
PAPieter Annaert
Pieter Annaert
ASAnne Smits
Anne Smits
Background: Serum creatinine (Scr) centile values were recently described in a cohort of 1136 (near)-term neonates that underwent therapeutic hypothermia (TH) because of moderate to severe hypoxic-ischemic encephalopathy. Recent methodological progress enables conversion of these Scr centiles to estimated glomerular filtration rate (eGFR) values. Methods: Scr centiles in the TH dataset during the first 10 days of life were converted to eGFR values, using the Schwartz formula, with the Smeets k-value (0.31) and fixed body length (50 cm) to generate postnatal reference eGFR values, centiles, and an equation for median eGFRs. These findings were compared to published eGFR data in term controls. Results: A polynomial function was estimated: $$\mathrm{eGFR} \left(\frac{\mathrm{mL}}{\mathrm{min}}\bullet 1.73{ \mathrm{m}}^{2}\right)=9.1667+7.1173 -0.3439{x}^{2},(x=\mathrm{days})$$ eGFR mL min ∙ 1.73 m 2 = 9.1667 + 7.1173 - 0.3439 x 2 , ( x = days ) for eGFR in TH neonates. The median eGFR increases 2- to threefold over the first week (day 1: 16.1; day 2: 19.4; day 7: 41.2 mL/min∙1.73 m 2 ), while the polynomial function does not fully reflect the interindividual variability in eGFR values (intra-day variability is also 2- to threefold). Patterns in acute kidney injury (AKI) TH cases differ significantly from non-AKI TH cases. Based on pooling of published eGFR data, this was compared to a function in healthy term neonates: $$\mathrm{eGFR} \left(\frac{\mathrm{mL}}{\mathrm{min}}\bullet 1.73 {\mathrm{m}}^{2}\right)=14.2167+6.7644-0.3901{x}^{2}(x=\mathrm{days})$$ eGFR mL min ∙ 1.73 m 2 = 14.2167 + 6.7644 - 0.3901 x 2 ( x = days ) (day 1: 20; day 2: 26; day 7: 42 mL/min/1.73 m 2 ). Conclusions: Based on a pooled dataset in TH cases, we converted Scr centiles to eGFR centiles. Based on median values, this resulted in a polynomial function in TH cases, compared to healthy term neonates. This eGFR function enables precision pharmacotherapy for GFR-cleared drugs in this vulnerable population. Graphical

5 August 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
MHMiao‐Chan Huang
Miao‐Chan Huang
JMJulia Macente
Julia Macente
SHSofie Heylen
Sofie Heylen
CNChen Ning
Chen Ning
KVKristof De Vos
Kristof De Vos
PAPieter Annaert
Pieter Annaert
Bosentan is the first approved oral medication for pulmonary arterial hypertension, yet the black‐box warning on its labeling implies a substantial risk of liver injury associated with bosentan exposure. The risk assessment of bosentan‐induced liver injury requires a thorough understanding of the underlying mechanisms, for which there is accumulating evidence. Integrating these mechanisms with clinical liver bosentan concentration would enable a more dynamic and relevant risk assessment. This study designed a workflow of physiologically−based pharmacokinetic (PBPK) model development to capture bosentan's hepatic disposition and predict the (intra)hepatic bosentan exposure. Specifically, clinical plasma and excretion data of bosentan were used to minimize the uncertainty in estimating the hepatic clearance. The model predictions were well overlapped with observations in the systemic circulation and excretion. Furthermore, the model‐derived intrinsic hepatic clearance was comparable with the one derived from a clinical study. These results reflected confidence in the model's capability to predict hepatic bosentan exposure. The model‐simulated steady‐state unbound exposure to bosentan in hepatocytes and liver tissue ranged from 1.65 to 34.1 ng/mL following twice‐daily 125‐mg oral doses. The ratio of the simulated unbound concentration between the liver matrices and systemic plasma was between 0.80 and 2.93 across the therapeutic dosing regimens. In summary, a bosentan PBPK model was successfully developed with the designed workflow and was able to predict the hepatic disposition of bosentan. The developed model can be applied to generate hepatic bosentan exposure that bridges the toxicological mechanistic findings from in vitro to in vivo, assisting in risk assessment.